About XOMA Corporation
XOMA Corporation is a company based in Berkeley (United States) founded in 1981.. The company has 13 employees as of December 31, 2024. XOMA Corporation has completed 6 acquisitions, including Generation Bio, Kinnate Biopharma and Lava Therapeutics. XOMA Corporation offers products and services including Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody. XOMA Corporation operates in a competitive market with competitors including Neurocrine, argenx, Crinetics, MacroGenics and Alexion, among others.
- Headquarter Berkeley, United States
- Employees 13 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xoma Royalty Corporation
-
Annual Revenue
$28.49 M498.72as on Dec 31, 2024
-
Net Profit
$-13.82 M66.15as on Dec 31, 2024
-
EBITDA
$-39.76 M-89.44as on Dec 31, 2024
-
Latest Funding Round
$1.9 M (USD), Post-IPO
Oct 14, 2020
-
Investors
SVB
& 1 more
-
Employee Count
13
as on Dec 31, 2024
-
Investments & Acquisitions
Generation Bio
& 5 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of XOMA Corporation
XOMA Corporation is a publicly listed company on the NASDAQ with ticker symbol XOMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of XOMA Corporation
XOMA Corporation offers a comprehensive portfolio of products and services, including Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Service for acquiring rights to biotech royalties and milestones.
Platform offering phage display technology for drug development.
Therapeutic asset for potential royalty and milestone payments.
Antibody asset available for licensing in drug candidates.
Unlock access to complete
Unlock access to complete
Funding Insights of XOMA Corporation
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $1.9M
-
First Round
First Round
(10 May 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - XOMA Corporation | Valuation |
investors |
|
| May, 2018 | Amount | Debt – Conventional - XOMA Corporation | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in XOMA Corporation
XOMA Corporation has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SVB and Rezolute. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
Founded Year | Domain | Location | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by XOMA Corporation
XOMA Corporation has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Generation Bio, Kinnate Biopharma and Lava Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cytokine-based immunotherapies for cancer treatment are developed.
|
2023 | ||||
|
Small molecule therapeutics for cancer treatment are developed.
|
2018 | ||||
|
Gene therapies for rare liver and eye diseases are developed.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - XOMA Corporation
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xoma Corporation Comparisons
Competitors of XOMA Corporation
XOMA Corporation operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, argenx, Crinetics, MacroGenics and Alexion, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xoma Corporation
Frequently Asked Questions about XOMA Corporation
When was XOMA Corporation founded?
XOMA Corporation was founded in 1981 and raised its 1st funding round 37 years after it was founded.
Where is XOMA Corporation located?
XOMA Corporation is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
How many employees does XOMA Corporation have?
As of Dec 31, 2024, the latest employee count at XOMA Corporation is 13.
What is the annual revenue of XOMA Corporation?
Annual revenue of XOMA Corporation is $28.49M as on Dec 31, 2024.
What does XOMA Corporation do?
XOMA Corporation was founded in 1981 and is headquartered in Berkeley, United States. Operations focus on biotechnology, with antibody-based therapeutics developed for endocrine and metabolic disorders. The pipeline features XOMA-358, a drug candidate in Phase 2 trials for congenital hyperinsulinism and post-bariatric surgery hyperinsulinism. Development efforts target unmet needs in these therapeutic areas through innovative antibody engineering.
Who are the top competitors of XOMA Corporation?
XOMA Corporation's top competitors include argenx, Crinetics and Neurocrine.
What products or services does XOMA Corporation offer?
XOMA Corporation offers Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody.
Is XOMA Corporation publicly traded?
Yes, XOMA Corporation is publicly traded on NASDAQ under the ticker symbol XOMA.
How many acquisitions has XOMA Corporation made?
XOMA Corporation has made 6 acquisitions, including Generation Bio, Kinnate Biopharma, and Lava Therapeutics.
Who are XOMA Corporation's investors?
What is XOMA Corporation's ticker symbol?
The ticker symbol of XOMA Corporation is XOMA on NASDAQ.